Tarsier Pharma Ltd. (TARX) IPO filing analysis

One-minute decisionBASIC RESEARCHSource completeness · 88%

IPO research

Tarsier Pharma is proposing an NYSE IPO of 5,555,555 ordinary shares at an estimated $8.00–$10.00 per share. The company is a loss-making, late-clinical-stage biopharmaceutical issuer whose lead candidate has not met its primary Phase 3 endpoint; substantial clinical, regulatory, financing and dilution risks remain.

Tarsier Pharma’s preliminary IPO contemplates 5,555,555 ordinary shares at $8.00–$10.00 per share and a proposed NYSE listing under TARX.

Where does the money go?Awaiting verificationF-1/A · 2026-07-16

Ownership and votingAwaiting verified holder data— economic · — voting

Next disclosed checkpointEffectiveness of the registration statement, pricing and closing of the proposed IPO; dates are not yet supplied.F-1/A · 2026-07-16

Capital destination

Awaiting verification

F-1/A · 2026-07-16

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · F-1/A ↗

Next checkEffectiveness of the registration statement, pricing and closing of the proposed IPO; dates are not yet supplied.

Latest filing2026-07-16

Capital destination

Awaiting verification

F-1/A · 2026-07-16

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · F-1/A ↗

BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters

NOT YET DISCLOSED

Names not yet published

Fully diluted valuation bridge

Status	Reference
Awaiting verification	Source ↗

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · F-1/A ↗

Holder data awaits verification

Before the offering, Daphne Haim-Langford beneficially owns 29.8%; directors and executive officers as a group own 33.4%. Alkaloida Chemical Company owns 20.06%, Oriella 10.8% and AJ Tarsier Investment 8.13%. No different voting rights are disclosed. · 2026-07-16

Before the offering, Daphne Haim-Langford beneficially owns 29.8%; directors and executive officers as a group own 33.4%. Alkaloida Chemical Company owns 20.06%, Oriella 10.8% and AJ Tarsier Investment 8.13%. No different voting rights are disclosed.

One disclosed holder; not a complete ownership distribution.Check the source · F-1/A ↗

Conditional lock-up timeline

Status	Reference
Awaiting verification	Source ↗

Financial quality and runway

Status	Reference
Awaiting verification	Source ↗

Latest filing update

Loading saved filing update…

SEC filing history

Loading filing history…

Risk 1

The company expects continued substantial losses and estimates $65–$85 million may be required to execute its TRS01 commercialization plan.

Potential impact: Awaiting verification
Monitor: Effectiveness of the registration statement, pricing and closing of the proposed IPO; dates are not yet supplied.
Evidence: RISK FACTORS ↗

SEC EDGAR

F-1/A

2026-07-16

Open SEC filing ↗